Venture capital firm Vertex Ventures, backed by Singapore state investor Temasek, is set to raise nearly $500 million for a new fund that will invest in efforts to step up China's domestic tech ...
Vertex saw disappointments in 2022, that may be about to change. Profitability may improve as onerous hedging rolled off for Q4. Shares could double from here to around $18 on my estimates (range: $10 ...
AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback